Provention Bio Stock News

Healthcare > Biotechnology

Buy PRVB

*Your capital is at risk

$24.98

+0 (+0%)

At Close: Jul 24, 2023

Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals

07:30am, Monday, 02'nd Nov 2020

RED BANK, N.J., Nov. 2, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the completio

Provention Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020

07:30am, Thursday, 29'th Oct 2020

RED BANK, N.J., Oct. 29, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that it will

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by